Peptide transport mechanisms in cystic fibrosis and normal human lung

D. A. Groneberg, Q. T. Dinh, P. R. Eynott, F. Doring, H. Daniel, P. J. Barnes, K. F. Chung, A. Fischer (Berlin, Freising, Germany; London, United Kingdom)

Source: Annual Congress 2001 - Airway epithelial cell biology
Session: Airway epithelial cell biology
Session type: Thematic Poster Session
Number: 575
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. A. Groneberg, Q. T. Dinh, P. R. Eynott, F. Doring, H. Daniel, P. J. Barnes, K. F. Chung, A. Fischer (Berlin, Freising, Germany; London, United Kingdom). Peptide transport mechanisms in cystic fibrosis and normal human lung. Eur Respir J 2001; 16: Suppl. 31, 575

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Distribution and characterisation of lung mast cells in cystic fibrosis
Source: Annual Congress 2009 - Airway inflammation and host defence
Year: 2009

New insights into the pathophysiology of lung disease in cystic fibrosis patients
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=1
Year: 2006

Increased epithelial production of LPLUNC1 in cystic fibrosis lung disease
Source: Annual Congress 2011 - Epithelial cell biology
Year: 2011


Cystic fibrosis lung disease: from molecular defect to abnormal mucocilliary clearance
Source: Annual Congress 2007 - PG4 - Paediatric respiratory medicine: cystic fibrosis – the basics
Year: 2007



Targeting cystic fibrosis inflammation in the age of CFTR modulators: focus on macrophages
Source: Eur Respir J, 57 (6) 2003502; 10.1183/13993003.03502-2020
Year: 2021



Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis
Source: Eur Respir J, 57 (1) 1902426; 10.1183/13993003.02426-2019
Year: 2021



The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects
Source: Eur Respir Rev, 30 (161) 210055; 10.1183/16000617.0055-2021
Year: 2021



Investigation of the status of cystic fibrosis airway epithelial cells
Source: Annual Congress 2008 - Multigenic expression analyses: a guide for diagnosis and therapy
Year: 2008


What damages the cystic fibrosis lung epithelium: host or microbe?
Source: Virtual Congress 2021 – Innate immunity and lung epithelial repair: what really happens?
Year: 2021


Effects of flow-dependent and threshold PEP on lung functions in cystic fibrosis
Source: Eur Respir J 2003; 22: Suppl. 45, 332s
Year: 2003

Improving airway clearance in cystic fibrosis lung disease
Source: Eur Respir Monogr 2014; 64: 169-187
Year: 2014


Is ceramide the missing link between the molecular defect and the lung disease of cystic fibrosis?
Source: Breathe 2008; 4: 365
Year: 2008

Bacterial infection and lung function in patients with cystic fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 615s
Year: 2005

Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration
Source: Eur Respir J, 59 (2) 2100185; 10.1183/13993003.00185-2021
Year: 2022



The lung clearance index correlates with markers of pulmonary deterioration in patients with cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children
Year: 2013

Comparison of progression in lung structure and lung function in children and adolescents with cystic fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 714s
Year: 2006

Long-term clearance from small airways in patients with cystic fibrosis
Source: Eur Respir J 2005; 25: 317-323
Year: 2005



Cystic fibrosis transmembrane conductance regulator pharmacotherapy
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=88
Year: 2006